IMARC Celebrates 20 Years of Supporting Clinical Research

STRONGSVILLE, Ohio, Nov. 12, 2018 (GLOBE NEWSWIRE) — IMARC, a leading clinical research organization, is entering into its 20th year of ensuring compliance for medical device companies.

IMARC has supported hundreds of clinical research projects during this time while maintaining a stellar record with the FDA. Not a single FDA warning letter has been issued to any of the clinical sites or clients with which they’ve worked.

IMARC CEO Sandra Maddock founded IMARC in 1999 after first working in critical care nursing and then as a research coordinator for a large cardiology practice. She realized there was a lack of standardized training and quality procedures protecting human subjects and complying with regulations.

Since then, IMARC has evolved from a largely one-woman operation to a successful mid-sized full service contract research organization (CRO) that works with some of the largest medical device companies in the world.

IMARC provides expert third-party oversight and clinical research support throughout the clinical trial lifecycle to ensure the protection of human subjects, the integrity of the data, and acceptance of the study results worldwide. Its services include monitoring, auditing, consulting, training, safety management, data management, project planning, site support and more.

“IMARC is committed to continuing this important work for our clients and investigators across the globe,” Maddock said. “As the clinical research field evolves to include more global players and new trends like wearable technologies, the need for both compliance and innovation has never been greater. We are thrilled to be part of these exciting advancements, and we can’t wait to see what the future holds.”

To learn more about IMARC’s comprehensive clinical research services, visit imarcresearch.com.

Contact:
John Lehmann, Business Development Manager
jlehmann@imarcresearch.com
440-801-1540

Ads